Reshma Kewalramani - 06 Aug 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
06 Aug 2025
Transactions value $
$3,895,768
Form type
4
Date filed
07 Aug 2025, 16:23
Previous filing
28 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kewalramani Reshma CEO & President, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 2025-08-07 0001735944

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Purchase $1.67M +4.29K +4.05% $389.08 110K 06 Aug 2025 Direct F1, F2
transaction VRTX Common Stock Purchase $2.23M +5.71K +5.18% $389.95 116K 06 Aug 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43).
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
F3 Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53).